MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
Want to see MLTX full AI Analyst Report?
MLTX Stock Chart & Stats
$17.79
-$0.83(-1.65%)
At close: 4:00 PM EST
$17.79
-$0.83(-1.65%)
Day’s Range― - ―
52-Week Range$5.95 - $62.75
Previous CloseN/A
Volume45.38K
Average Volume (3M)1.11M
Market Cap
$1.29B
Enterprise Value$1.02B
Total Cash (Recent Filing)$393.97M
Total Debt (Recent Filing)$75.71M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
May 07, 2026EPS Estimate
-0.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding71,727,875
10 Day Avg. Volume1,482,979
30 Day Avg. Volume1,105,276
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio-4.33
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-454.53
Enterprise Value/Ebitda-4.63
Forecast
1Y Price Target
$28.57Price Target Upside60.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-3.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data And Head-to-head TrialsPooled Phase 3 results, supportive Phase 2 findings, and a late-stage active-comparator study showing symptom and pain improvements versus a leading competitor could materially raise perceived value and support a biologics license application and priority review if replicated across indications.
Distinct Mechanism And DesignAnalyst notes sonelokimab targets both IL-17A and IL-17F with a small nanobody structure and albumin-binding design, features that could deliver stronger disease control and a differentiated product profile versus many existing therapies.
Unmet Medical NeedAnalyst highlights that hidradenitis suppurativa is severely under-diagnosed and undertreated, indicating a large unmet medical need and a sizeable commercial opportunity for an effective therapy like sonelokimab.
Bears Say
Clinical Trial VariabilityPronounced placebo responses in one study arm and differences in measurement methods across trials complicate direct comparisons and create uncertainty about the true magnitude of sonelokimab's treatment benefit.
Financing RiskLimited cash runway relative to cash burn raises the likelihood of additional financing needs, which could dilute shareholders or exert downward pressure on the stock.
Regulatory Evidence BurdenRegulatory expectations to include long-term data and to address a missed primary goal in one study increase the evidence burden and could complicate the approval pathway and timing for a filing.
MoonLake Immunotherapeutics News
MLTX FAQ
What was MoonLake Immunotherapeutics’s price range in the past 12 months?
MoonLake Immunotherapeutics lowest stock price was $5.95 and its highest was $62.75 in the past 12 months.
What is MoonLake Immunotherapeutics’s market cap?
MoonLake Immunotherapeutics’s market cap is $1.29B.
When is MoonLake Immunotherapeutics’s upcoming earnings report date?
MoonLake Immunotherapeutics’s upcoming earnings report date is May 07, 2026 which is in 20 days.
How were MoonLake Immunotherapeutics’s earnings last quarter?
MoonLake Immunotherapeutics released its earnings results on Feb 22, 2026. The company reported -$0.93 earnings per share for the quarter, beating the consensus estimate of -$0.964 by $0.034.
Is MoonLake Immunotherapeutics overvalued?
According to Wall Street analysts MoonLake Immunotherapeutics’s price is currently Undervalued.
Does MoonLake Immunotherapeutics pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
What is MoonLake Immunotherapeutics’s EPS estimate?
MoonLake Immunotherapeutics’s EPS estimate is -0.89.
How many shares outstanding does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics has 71,727,875 shares outstanding.
What happened to MoonLake Immunotherapeutics’s price movement after its last earnings report?
MoonLake Immunotherapeutics reported an EPS of -$0.93 in its last earnings report, beating expectations of -$0.964. Following the earnings report the stock price went up 4.541%.
Which hedge fund is a major shareholder of MoonLake Immunotherapeutics?
Currently, no hedge funds are holding shares in MLTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MoonLake Immunotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.57 (60.60% Upside)
$28.57 (60.60% Upside)
Blogger Sentiment
Bullish
MLTX Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 12.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $65.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.87%
12-Months-Change
Fundamentals
Return on Equity
-67.12%
Trailing 12-Months
Asset Growth
-11.19%
Trailing 12-Months
Company Description
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MLTX Stock 12 Month Forecast
Average Price Target
$28.57
▲(60.60% Upside)
Technical Analysis
Protagonist Therapeutics
―
Zai Lab
―
Apellis Pharmaceuticals
―
Crinetics Pharmaceuticals
―
―
Ownership Overview
14.35% Insiders
2.22% Mutual Funds
0.26% Other Institutional Investors
82.36% Public Companies and
Individual Investors